A New Wave in Treatment of Vascular Occlusive Disease: Biodegradable Stents-Clinical Experience and Scientific Principles

Journal of Vascular and Interventional Radiology

Volumn 20, Issue 3, 2009, Pages 315-324

  Brown, David A ^a   Lee, Edward W ^a   Loh, Christopher T ^a   Kee, Stephen T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORONARY STENT; DRUG ELUTING STENT; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RESTENOSIS; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY;

ABSORBABLE IMPLANTS; ARTERIAL OCCLUSIVE DISEASES; BLOOD VESSEL PROSTHESIS; CLINICAL TRIALS AS TOPIC; HUMANS; STENTS;

EID: 60649097103     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvir.2008.11.007     Document Type: Review

References (95)

1. Dotter C.T., and Judkins M.P. Transluminal treatment of arteriosclerotic obstruction. description of a new technic and a preliminary report of its application. Circulation 30 (1964) 654-670
2. Gruentzig A.R. Percutaneous transluminal coronary angioplasty. Semin Roentgenol 16 (1981) 152-153
3. Sigwart U., Puel J., Mirkovitch V., Joffre F., and Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 316 (1987) 701-706
4. Palmaz J.C., Richter G.M., Noldge G., Kauffmann G.W., and Wenz W. Intraluminal Palmaz stent implantation. The first clinical case report on a balloon-expanded vascular prosthesis. Radiologe 27 (1987) 560-563
5. O'Laughlin M.P., Perry S.B., Lock J.E., and Mullins C.E. Use of endovascular stents in congenital heart disease. Circulation 83 (1991) 1923-1939
6. Mullins C.E., O'Laughlin M.P., Vick III G.W., et al. Implantation of balloon-expandable intravascular grafts by catheterization in pulmonary arteries and systemic veins. Circulation 77 (1988) 188-199
7. Serruys P.W., Strauss B.H., Beatt K.J., et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med 324 3 (1991) 13-17
8. Hoffmann R., Mintz G.S., Dussaillant G.R., et al. Patterns and mechanisms of in-stent restenosis: a serial intravascular ultrasound study. Circulation 94 (1996) 1247-1254
9. Hall P., Nakamura S., Maiello L., et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 93 15 (1996) 215-222
10. Colombo A., Hall P., Nakamura S., et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 91 (1995) 1676-1688
11. Holmes Jr. D.R., Savage M., LaBlanche J.M., et al. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 106 (2002) 1243-1250
12. Grube E., Silber S., Hauptmann K.E., et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 107 (2003) 38-42
13. Morice M.C., Serruys P.W., Sousa J.E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
14. Maisel W.H. Unanswered questions-drug-eluting stents and the risk of late thrombosis. N Engl J Med 356 (2007) 981-984
15. In: Pfisterer M., Kaiser C., Bader F., et al. (Eds). Late clinical events related to late stent thrombosis after stopping clopidogrel: prospective randomized comparison between drug-eluting versus bare-metal stenting (2006) Presented at the American College of Cardiology 55th Annual Scientific Session; March 11-14, Atlanta, GA
16. Kedia G., and Lee M.S. Stent thrombosis with drug-eluting stents: a re-examination of the evidence. Catheter Cardiovasc Intervent 69 (2007) 782-789
17. Center for Devices and Radiological Health. Circulatory system devices panel: CDRH Advisory Committee, Food and Drug Administration (2006) December 7-8, Gaithersburg, MD
18. Stack R.S., Califf R.M., Phillips H.R., et al. Interventional cardiac catheterization at Duke Medical Center. Am J Cardiol 62 (1988) 3F-24F
19. Tsuji T., Tamai H., and Kyo E. The effect of PLLA stent design on neointimal hyperplasia. (abstr.). J Cardiol 32 (1998) 235A
20. Yamawaki T., Shimokawa H., Kozai T., et al. Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J Am Coll Cardiol 32 (1998) 780-786
21. Tamai H., Igaki K., Kyo E., et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 102 (2000) 399-404
22. van der Giessen W.J., Lincoff A.M., Schwartz R.S., et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 94 (1996) 1690-1697
23. Tsuji T., Tamai H., and Igaki K. One year follow-up of biodegradable self-expanding stent implantation in humans. J Am Coll Cardiol 37 (2001) 47A
24. In: Capek J. (Ed). The Guidant-BVS bioabsorbable stent program: Biotronik (2006) Presented at the Cardiovascular Research Technologies Annual Meeting, March 4-6, Washington, DC
25. Abbott Announces Positive One-Year Results from the World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent. Presented at Transcatheter Cardiovascular Therapeutics; October 20-25, 2007; Washington DC.
26. Vogt F., Stein A., Rettemeier G., et al. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur Heart J 25 (2004) 1330-1340
27. Tanimoto S., Serruys P.W., Thuesen L., et al. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. Cathet Cardiovasc Intervent 70 (2007) 515-523
28. Waksman R. Update on bioabsorbable stents: from bench to clinical. J Interv Cardiol 19 (2006) 414-421
29. Schultz R. REVA Medical, Inc., Bioabsorbable Technology (2006) Presented at the Cardiovascular Research Technologies Annual Meeting, March 4-6, Washington, DC.
30. Bunger C.M., Grabow N., Kroger C., et al. Iliac anastomotic stenting with a sirolimus-eluting biodegradable poly-L-lactide stent: a preliminary study after 6 weeks. J Endovasc Ther 13 (2006) 630-639
31. Bunger C.M., Grabow N., Sternberg K., et al. Iliac anastomotic stenting with a biodegradable poly-L-lactide stent: a preliminary study after 1 and 6 weeks. J Endovasc Ther 13 (2006) 539-548
32. Grabow N., Bunger C.M., Schultze C., et al. A biodegradable slotted tube stent based on poly(L: -lactide) and poly(4-hydroxybutyrate) for rapid balloon-expansion. Ann Biomed Eng 35 (2007) 2031-2038
33. Bunger C., Grabow N., Sternberg K., et al. A biodegradable stent based on poly(l-lactide) and poly(4-hydroxybutyrate) for peripheral vascular application: preliminary experience in the pig. J Endovasc Ther 14 (2007) 725-733
34. Ye Y.W., Landau C., Willard J.E., et al. Bioresorbable microporous stents deliver recombinant adenovirus gene transfer vectors to the arterial wall. Ann Biomed Eng 26 (1998) 398-408
35. Klugherz B.D., Jones P.L., Cui X., et al. Gene delivery from a DNA controlled-release stent in porcine coronary arteries. Nat Biotechnol 18 (2000) 1181-1184
36. Klugherz B.D., Song C., DeFelice S., et al. Gene delivery to pig coronary arteries from stents carrying antibody-tethered adenovirus. Hum Gene Ther 13 (2002) 443-454
37. Perlstein I., Connolly J.M., Cui X., et al. DNA delivery from an intravascular stent with a denatured collagen-polylactic-polyglycolic acid-controlled release coating: mechanisms of enhanced transfection. Gene Ther 10 (2003) 1420-1428
38. Johnson T.W., Wu Y.X., Herdeg C., et al. Stent-based delivery of tissue inhibitor of metalloproteinase-3 adenovirus inhibits neointimal formation in porcine coronary arteries. Arterioscler Thromb Vasc Biol 25 (2005) 754-759
39. Walter D.H., Cejna M., Diaz-Sandoval L., et al. Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis. Circulation 110 (2004) 36-45
40. Sharif F., Hynes S.O., McMahon J., et al. Gene-eluting stents: comparison of adenoviral and adeno- associated viral gene delivery to the blood vessel wall in vivo. Hum Gene Ther 17 (2006) 741-750
41. Mousa A.Y., Beauford R.B., Flores L., et al. Endovascular treatment of iliac occlusive disease: review and update. Vascular 15 (2007) 5-11
42. Geraghty P.J. Bioabsorbable stenting for peripheral arterial occlusive disease. Perspect Vasc Surg Endovasc Ther 18 (2006) 295-298
43. Biamino G., Schmidt A., and Scheinert D. Treatment of SFA lesions with PLLA biodegradable stents: results of the PERSEUS study. J Endovasc Ther 12 suppl I (2005) 5
44. Vitale J.J. Magnesium deficiency and cardiovascular disease. Lancet 340 (1992) 1224-1225
45. Stone P., and Lord Jr. J.W. An experimental study of the thrombogenic properties of magnesium and magnesium-aluminum wire in the dog's aorta. Surgery 30 (1951) 987-993
46. Erne P., Schier M., and Resink T.J. The road to bioabsorbable stents: reaching clinical reality?. Cardiovasc Intervent Radiol 29 (2006) 11-16
47. Heublein B., Rohde R., Kaese V., et al. Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology?. Heart 89 (2003) 651-656
48. Bosiers M., Deloose K., Verbist J., and Peeters P. First clinical application of absorbable metal stents in the treatment of critical limb ischemia: 12-month results. Vasc Disease Manage 2 (2006) 86-91
49. Peeters P., Bosiers M., Verbist J., Deloose K., and Heublein B. Preliminary results after application of absorbable metal stents in patients with critical limb ischemia. J Endovasc Ther 12 (2005) 1-5
50. Erbel R., Di Mario C., Bartunek J., et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 369 (2007) 1869-1875
51. McMahon C.J., El-Said H.G., Grifka R.G., et al. Redilation of endovascular stents in congenital heart disease: factors implicated in the development of restenosis and neointimal proliferation. J Am Coll Cardiol 38 (2001) 521-526
52. Schranz D., Zartner P., Michel-Behnke I., and Akinturk H. Bioabsorbable metal stents for percutaneous treatment of critical recoarctation of the aorta in a newborn. Cathet Cardiovasc Intervent 67 (2006) 671-673
53. Zartner P., Cesnjevar R., Singer H., and Weyand M. First successful implantation of a biodegradable metal stent into the left pulmonary artery of a preterm baby. Cathet Cardiovasc Intervent 66 (2005) 590-594
54. Peuster M., Hesse C., Schloo T., et al. Long-term biocompatibility of a corrodible peripheral iron stent in the porcine descending aorta. Biomaterials 27 (2006) 4955-4962
55. Garza L., Aude Y.W., and Saucedo J.F. Can we prevent in-stent restenosis?. Curr Opin Cardiol 17 (2002) 518-525
56. Mehran R., Dangas G., Abizaid A.S., et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 100 (1999) 1872-1878
57. Kastrati A., Schomig A., Elezi S., et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 30 (1997) 1428-1436
58. Kobayashi Y., De Gregorio J., Kobayashi N., et al. Stented segment length as an independent predictor of restenosis. J Am Coll Cardiol 34 (1999) 651-659
59. Rajagopal V., and Rockson S.G. Coronary restenosis: a review of mechanisms and management. Am J Med 115 (2003) 547-553
60. Bermejo J., Botas J., Garcia E., et al. Mechanisms of residual lumen stenosis after high-pressure stent implantation: a quantitative coronary angiography and intravascular ultrasound study. Circulation 98 (1998) 112-118
61. Leon M.B., Baim D.S., Popma J.J., et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 339 (1998) 1665-1671
62. Fattori R., and Piva T. Drug-eluting stents in vascular intervention. Lancet 361 (2003) 247-249
63. Rollins B.J. Chemokines. Blood 90 (1997) 909-928
64. Libby P., and Simon D.I. Inflammation and thrombosis: the clot thickens. Circulation 103 (2001) 1718-1720
65. Virmani R., and Farb A. Pathology of in-stent restenosis. Curr Opin Lipidol 10 (1999) 499-506
66. Kereiakes D.J., Lincoff A.M., Miller D.P., et al. Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators. Circulation 97 (1998) 857-864
67. Mitra A.K., and Agrawal D.K. In stent restenosis: bane of the stent era. J Clin Pathol 59 (2006) 232-239
68. Fuster V., Falk E., Fallon J.T., et al. The three processes leading to post PTCA restenosis: dependence on the lesion substrate. Thromb Haemost 74 (1995) 552-559
69. Cipollone F., Marini M., Fazia M., et al. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol 21 (2001) 327-334
70. Furukawa Y., Matsumori A., Ohashi N., et al. Anti-monocyte chemoattractant protein-1/monocyte chemotactic and activating factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries. Circ Res 84 (1999) 306-314
71. Mintz G.S., Popma J.J., Pichard A.D., et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation 94 (1996) 35-43
72. Nakamura S., Colombo A., Gaglione A., et al. Intracoronary ultrasound observations during stent implantation. Circulation 89 (1994) 2026-2034
73. Kimura T., Abe K., Shizuta S., et al. Long-term clinical and angiographic follow-up after coronary stent placement in native coronary arteries. Circulation 105 (2002) 2986-2991
74. Saia F., Lemos P.A., Hoye A., et al. Clinical outcomes for sirolimus-eluting stent implantation and vascular brachytherapy for the treatment of in-stent restenosis. Cathet Cardiovasc Intervent 62 (2004) 283-288
75. Doriot P.A., Dorsaz P.A., and Verin V. A morphological-mechanical explanation of edge restenosis in lesions treated with vascular brachytherapy. Cardiovasc Radiat Med 4 (2003) 108-115
76. Waksman R. Late thrombosis after radiation: sitting on a time bomb. Circulation 100 (1999) 780-782
77. Leon M.B., Popma J., and O'Shaughnessy C. Quantitative angiographic outcomes after Gianturco-Roubin stent implantation in complex lesions. Circulation 96 suppl 1 (1997) I-593
78. Thuesen L., Andersen H.R., Krusell L.R., et al. Randomized comparison of the coil-design Crossflex and the tubular NIR stent. Cathet Cardiovasc Intervent 59 (2003) 8-12
79. Lansky A.J., Roubin G.S., O'Shaughnessy C.D., et al. Randomized comparison of GR-II stent and Palmaz-Schatz stent for elective treatment of coronary stenoses. Circulation 102 (2000) 1364-1368
80. Tamai H., Igaki K., Tsuji T., et al. A biodegradable poly-l-lactic acid coronary stent in the porcine coronary artery. J Interv Cardiol 12 (1999) 443-450
81. Peng T., Gibula P., Yao K.D., and Goosen M.F. Role of polymers in improving the results of stenting in coronary arteries. Biomaterials 17 (1996) 685-694
82. Venkatraman S.S., Tan L.P., Joso J.F., Boey Y.C., and Wang X. Biodegradable stents with elastic memory. Biomaterials 27 (2006) 1573-1578
83. McKenna C.J., Wilson S.H., Camrud A.R., et al. Neointimal response following rotational atherectomy compared to balloon angioplasty in a porcine model of coronary in-stent restenosis. Cathet Cardiovasc Diagn 45 (1998) 332-336
84. Post M.J., de Graaf-Bos A.N., Posthuma G., et al. Interventional thermal injury of the arterial wall: unfolding of von Willebrand factor and its increased binding to collagen after 55 degrees C heating. Thromb Haemost 75 (1996) 515-519
85. Post M.J., de Graaf-Bos A.N., van Zanten H.G., et al. Thrombogenicity of the human arterial wall after interventional thermal injury. J Vasc Res 33 (1996) 156-163
86. Douek P.C., Correa R., Neville R., et al. Dose-dependent smooth muscle cell proliferation induced by thermal injury with pulsed infrared lasers. Circulation 86 (1992) 1249-1256
87. Schwartz R.S., Huber K.C., Murphy J.G., et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 19 (1992) 267-274
88. Schwartz R.S., Murphy J.G., Edwards W.D., et al. Restenosis after balloon angioplasty: a practical proliferative model in porcine coronary arteries. Circulation 82 (1990) 2190-2200
89. Konig A., Schiele T.M., Rieber J., et al. Stent design-related coronary artery remodeling and patterns of neointima formation following self-expanding and balloon-expandable stent implantation. Cathet Cardiovasc Intervent 56 (2002) 478-486
90. Foley D.P., Pieper M., Wijns W., et al. The influence of stent length on clinical and angiographic outcome in patients undergoing elective stenting for native coronary artery lesions; final results of the Magic 5L study. Eur Heart J 22 (2001) 1585-1593
91. de Feyter P.J., Kay P., Disco C., and Serruys P.W. Reference chart derived from post-stent-implantation intravascular ultrasound predictors of 6-month expected restenosis on quantitative coronary angiography. Circulation 100 (1999) 1777-1783
92. Stone G.W., Ellis S.G., Cox D.A., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 (2004) 221-231
93. Guelcher S.A., and Hollinger J.O. An introduction to biomaterials (2005), CRC Press, Boca Raton, FL
94. Lactel absorbable polymers. Chemical properties of select polymers. [Web site]. http://www.absorbables.com/properties.htm Accessed November 12, 2007
95. Grabow N., Bunger C.M., Sternberg K., et al. Mechanical properties of a biodegradable balloon-expandable stent from poly(L-lactide) for peripheral vascular applications. J Med Dev 1 (2007) 84-88